Clinical Trial Update: A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial update of galcanezumab in Japanese participants with migraine has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Galcanezumab (galcanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2020-08-24